Dexcom
Dexcom, Inc., a leading player in the diabetes care industry, is headquartered in the United States. Founded in 1999, the company has pioneered continuous glucose monitoring (CGM) technology, significantly enhancing diabetes management for patients worldwide. With a strong presence in North America, Europe, and Asia, Dexcom focuses on developing innovative solutions that empower individuals to take control of their health. The company's flagship products, including the Dexcom G6 and G7 CGM systems, offer real-time glucose monitoring with exceptional accuracy and ease of use. These devices are distinguished by their ability to provide users with actionable insights, helping to prevent hypoglycaemic events and improve overall glycaemic control. Dexcom's commitment to innovation has solidified its position as a market leader, recognised for its contributions to diabetes management and patient care.
DitchCarbon Score
How does Dexcom's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dexcom's score of 40 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dexcom's reported carbon emissions
In 2023, Dexcom, Inc. reported total carbon emissions of approximately 665,200 kg CO2e for Scope 1, 25,291,000 kg CO2e for Scope 2, and a significant 479,576,000 kg CO2e for Scope 3 emissions. This brings their total Scope 1 and 2 emissions to about 31,943,000 kg CO2e. The breakdown of Scope 1 emissions includes mobile combustion (1,848,000 kg CO2e), fugitive emissions (1,380,000 kg CO2e), and stationary combustion (3,400,000 kg CO2e). For Scope 2, the total market-based emissions were reported at 25,291,000 kg CO2e, primarily from purchased electricity. In terms of reduction initiatives, Dexcom has committed to near-term targets, although specific numerical targets were not disclosed. Notably, a previous commitment was removed, indicating a shift in their climate strategy. As of June 2023, they have not committed to a net-zero target. The company operates within the healthcare equipment and supplies sector and is headquartered in the United States. Dexcom's emissions data is self-reported and does not appear to be cascaded from a parent organisation. The company continues to monitor and report its emissions, aligning with industry standards for transparency and accountability in climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 2,044,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,371,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 1,257,000 | 0,000,000 | 0,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dexcom is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
